SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001214659-24-007877
Filing Date
2024-04-30
Accepted
2024-04-30 16:30:46
Documents
15
Period of Report
2024-04-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 g4302428k.htm   iXBRL 8-K 29014
2 EXHIBIT 4.1 ex4_1.htm EX-4.1 22069
3 EXHIBIT 10.1 ex10_1.htm EX-10.1 55814
  Complete submission text file 0001214659-24-007877.txt   305865

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE alzn-20240430.xsd EX-101.SCH 2991
5 XBRL LABEL FILE alzn-20240430_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE alzn-20240430_pre.xml EX-101.PRE 22343
18 EXTRACTED XBRL INSTANCE DOCUMENT g4302428k_htm.xml XML 3914
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

IRS No.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-40483 | Film No.: 24897776
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)